CSIMarket
 
Viracta Therapeutics Inc   (VIRX)
Other Ticker:  
 
 
Price: $0.9363 $0.22 30.988%
Day's High: $0.9499 Week Perf: -19.97 %
Day's Low: $ 0.74 30 Day Perf: -3.47 %
Volume (M): 196 52 Wk High: $ 2.38
Volume (M$): $ 184 52 Wk Avg: $1.02
Open: $0.74 52 Wk Low: $0.43



 Market Capitalization (Millions $) 36
 Shares Outstanding (Millions) 39
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -69
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Viracta Therapeutics Inc
Viracta Therapeutics Inc is a biopharmaceutical company that focuses on developing precision medicines for the treatment of viral-related cancers. The company uses its proprietary viral activation therapy (VAT) platform to target specific viral infections that contribute to the development and progression of certain cancers.

Viracta Therapeutics' novel approach involves combining antiviral agents with immunotherapies to specifically activate and destroy cancer cells that are infected with the Epstein-Barr virus (EBV) or the Kaposi's sarcoma-associated herpesvirus (KSHV). By targeting the virus within the cancer cells, the company aims to disrupt the viral genes responsible for tumor growth and drive a coordinated immune response against the infected cells.

The company's lead product candidate, nanatinostat, is being investigated in clinical trials for the treatment of lymphomas associated with the EBV infection. Viracta Therapeutics aims to expand its pipeline and develop additional therapies targeting other viral-related cancers, leveraging its VAT platform and expertise in precision medicine.

Overall, Viracta Therapeutics Inc is dedicated to developing innovative treatments that harness the power of the immune system to combat viral-related cancers and improve patient outcomes.


   Company Address: 2533 S. Coast Hwy. 101, Suite 210 Cardiff 92007 CA
   Company Phone Number: 400-8470   Stock Exchange / Ticker: NASDAQ VIRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Viracta Therapeutics' Nana-val Shows Promising Efficacy in EBV+ Peripheral T-Cell Lymphoma Treatment Trial

Published Mon, Apr 15 2024 12:01 PM UTC

In a groundbreaking development, Viracta Therapeutics has announced the positive topline results from Stage 1 of the NAVAL-1 Trial. This trial evaluated the efficacy and safety of Nana-val (nanatinostat in combination with valganciclovir) in patients suffering from relapsed or refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma.The data obtained from thi...

Clinical Study

Viracta Therapeutics Sees Rapid Enrollment Progress in NAVAL-1 Trial for Peripheral T-Cell Lymphoma

Published Thu, Feb 29 2024 1:00 PM UTC

In this article, we will discuss the recent achievement of Viracta Therapeutics, a leading biopharmaceutical company specializing in targeted treatments for cancer. Specifically, we will explore their progress in completing the second-stage enrollment into the peripheral T-cell lymphoma (PTCL) cohort of the NAVAL-1 trial. The article will outline the implications of this mil...

Clinical Study

A New Ray of Hope: Viracta Therapeutics Advances Nana-val as a Potential Game-Changer for Relapsed or Refractory EBV Peripheral T-cell Lymphoma

Published Thu, Jan 4 2024 1:00 PM UTC

Viracta Therapeutics: Advancing a Promising Treatment for Relapsed or Refractory EBV Peripheral T-cell Lymphoma Viracta Therapeutics, a leading clinical-stage biotechnology company, has provided an update on the progress of its innovative treatment, Nana-val, for patients with relapsed or refractory Epstein-Barr Virus (EBV) peripheral T-cell lymphoma. The company announced t...

Clinical Study

Viracta Therapeutics' Nana-val Secures Orphan Drug Designation, Revolutionizing Nasopharyngeal Carcinoma Treatment

Published Tue, Dec 12 2023 1:00 PM UTC



In a significant breakthrough for the field of cancer therapeutics, Viracta Therapeutics has recently announced that the United States Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for their groundbreaking drug, Nana-val, in the treatment of nasopharyngeal carcinoma (NPC). This distinction is notable as it marks the first time N...

Clinical Study

Nana-val Shines in Clinical Trial for EBV-Positive Solid Tumors: Breakthrough Treatment Offers Hope and Enhanced Efficacy through Innovative Dosing Regimen

Published Mon, Dec 4 2023 1:30 PM UTC

Viracta Therapeutics Announces Promising Interim Data for Nana-val in Treating Epstein-Barr Virus-Positive Solid Tumors
Viracta Therapeutics, a leading biotechnology company focused on innovative treatments for viral-associated cancers, has released interim data from their Phase 1b/2 clinical trial of Nana-val in patients with Epstein-Barr virus (EBV)-positive solid tumo...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com